Anti-respiratory syncytial virus antibodies, and methods of their generation and use
View Patent ↗Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.
1. An isolated antibody or an antigen-binding fragment thereof that specifically binds to Respiratory Syncytial Virus (RSV) F protein (F), wherein the antibody or the antigen-binding fragment thereof comprises:
(a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 947;
(b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 949;
(c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 951;
(d) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 955;
(e) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 957; and
(f) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 959, and
wherein the antibody or the antigen-binding fragment thereof further comprises:
(i) a heavy chain (HC) amino acid sequence that is at least 70% identical; at least 75% identical; at least 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99% identical; and/or all percentages of identity in between; to the amino acid sequence of SEQ ID NO: 946; and/or
(ii) a light chain (LC) amino acid sequence that is at least 70% identical; at least 75% identical; at least 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99% identical; and/or all percentages of identity in between; to the amino acid sequence of SEQ ID NO: 954.
2. The isolated antibody or antigen-binding fragment thereof of claim 1 having one or more of the following characteristics:
a) the antibody or antigen-binding fragment thereof cross-competes with said antibody or antigen-binding fragment thereof for binding to RSV-F;
b) the antibody or antigen-binding fragment thereof displays better binding affinity for the PreF form of RSV-F relative to the PostF form;
c) the antibody or antigen-binding fragment thereof displays a clean or low polyreactivity profile;
d) the antibody or antigen-binding fragment thereof displays neutralization activity toward RSV subtype A and RSV subtype B in vitro;
e) the antibody or antigen-binding fragment thereof displays antigenic site specificity for RSV-F at Site Ø, Site I, Site II, Site III, Site IV, or Site V;
f) the antibody or antigen-binding fragment thereof displays antigenic site specificity for RSV-F Site Ø, Site V, or Site III relative to RSV-F Site I, Site II, or Site IV;
g) at least a portion of the epitope with which the antibody or antigen-binding fragment thereof interacts comprises the α3 helix and β3/β4 hairpin of PreF;
h) the antibody or antigen-binding fragment thereof displays an in vitro neutralization potency (IC 50 ) of between about 0.5 microgram/milliliter (ug/ml) to about 5 ug/ml; between about 0.05 ug/ml to about 0.5 ug/ml; or less than about 0.05 mg/ml;
i) the binding affinity and/or epitopic specificity of the antibody or antigen-binding fragment thereof for any one of the RSV-F variants designated as 1, 2, 3, 4, 5, 6, 7, 8, 9, and DG in FIG. 7 A is reduced or eliminated relative to the binding affinity and/or epitopic specificity of said antibody or antigen-binding fragment thereof for the RSV-F or RSV-F DS-Cav1;
j) the antibody or antigen-binding fragment thereof displays a cross-neutralization potency (IC 50 ) against human metapneumovirus (HMPV);
k) the antibody or antigen-binding fragment thereof does not complete with D25, MPE8, palivisumab, motavizumab, or AM-14; or
l) the antibody or antigen-binding fragment thereof displays at least about 2-fold; at least about 3-fold; at least about 4-fold; at least about 5-fold; at least about 6-fold; at least about 7-fold; at least about 8-fold; at least about 9-fold; at least about 10-fold; at least about 15-fold; at least about 20-fold; at least about 25-fold; at least about 30-fold; at least about 35-fold; at least about 40-fold; at least about 50-fold; at least about 55-fold; at least about 60-fold; at least about 70-fold; at least about 80-fold; at least about 90-fold; at least about 100-fold; greater than about 100-fold; and folds in between any of the foregoing; greater neutralization potency (IC50) than D25 and/or palivizumab.
3. The isolated antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof comprises: at least two; at least three; at least 4; at least 5; at least 6; at least 7; at least 8; at least 9; at least 10; at least 11; or at least 12; of characteristics a) through l).
4. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises:
a) the heavy chain (HC) amino acid sequence of SEQ ID NO: 946; and/or
b) the light chain (LC) amino acid sequence of SEQ ID NO: 954.
5. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is at least 70% identical; at least 75% identical; at least 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99% identical; and/or all percentages of identity in between; to the antibody designated as Antibody Number 183 as disclosed in Table 6.
6. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is the antibody designated as Antibody Number 183 as disclosed in Table 6.
7. A multi-specific antibody comprising an antigen-binding fragment that specifically binds to RSV-F, wherein the antigen-binding fragment comprises:
(a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 947;
(b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 949;
(c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 951;
(d) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 955;
(e) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 957; and
(f) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 959.
8. The multi-specific antibody of claim 7 , wherein the multi-specific antibody is a bi-specific antibody.
9. The multi-specific antibody of claim 8 comprising a first immunoglobulin C H 3 domain (C H 3 1 ) and a second immunoglobulin C H 3 domain (C H 3 2 ), wherein the C H 3 1 and C H 3 2 differ by at least one amino acid.
10. The multi-specific antibody of claim 9 , wherein either the C H 3 1 or C H 3 2 comprises a mutation that reduces or abolishes Protein A binding.
11. The multi-specific antibody of claim 7 , wherein the antigen-binding fragment comprises:
a) the heavy chain (HC) amino acid sequence of SEQ ID NO: 946; and/or
b) the light chain (LC) amino acid sequence of SEQ ID NO: 954.
12. The multi-specific antibody of claim 7 , wherein the antigen-binding fragment is at least 70% identical; at least 75% identical; at least 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99% identical; and/or all percentages of identity in between; to an antigen-binding fragment of the antibody designated as Antibody Number 183 disclosed in Table 6.
13. A method of inhibiting fusion of a RSV with a cell, the method comprising contacting the RSV with an isolated antibody or antigen-binding fragment thereof that specifically binds to RSV-F, wherein the antibody or the antigen-binding fragment thereof comprises:
(a) a CDRH1 comprising the amino acid sequence of SEQ ID NO: 947;
(b) a CDRH2 comprising the amino acid sequence of SEQ ID NO: 949;
(c) a CDRH3 comprising the amino acid sequence of SEQ ID NO: 951;
(d) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 955;
(e) a CDRL2 comprising the amino acid sequence of SEQ ID NO: 957; and
(f) a CDRL3 comprising the amino acid sequence of SEQ ID NO: 959.
14. The method of claim 13 , wherein contacting the RSV with the one or more antibodies or antigen-binding fragments comprises administering the one or more antibodies or antigen-binding fragments to a patient that has been exposed to or at risk of acquiring an infection with RSV.
15. The method of claim 13 , wherein the isolated antibody or antigen-binding fragment thereof comprises:
a) the heavy chain (HC) amino acid sequence of SEQ ID NO: 946; and/or
b) the light chain (LC) amino acid sequence of SEQ ID NO: 954.
16. The method of claim 13 , wherein the isolated antibody or antigen-binding fragment thereof is at least 70% identical; at least 75% identical; at least 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99% identical; and/or all percentages of identity in between; to the antibody designated as Antibody Number 183 as disclosed in Table 6.
17. The method of claim 13 , wherein the isolated antibody or antigen-binding fragment thereof is the antibody designated as Antibody Number 183 as disclosed in Table 6.
18. The multi-specific antibody of claim 7 , wherein the antigen-binding fragment comprises:
(a) a heavy chain (HC) amino acid sequence that is at least 70% identical; at least 75% identical; at least 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99% identical; and/or all percentages of identity in between; to the amino acid sequence of SEQ ID NO: 946; and/or
(b) a light chain (LC) amino acid sequence that is at least 70% identical; at least 75% identical; at least 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99% identical; and/or all percentages of identity in between; to the amino acid sequence of SEQ ID NO: 954.
19. The method of claim 13 , wherein the isolated antibody or antigen-binding fragment thereof comprises:
(a) a heavy chain (HC) amino acid sequence that is at least 70% identical; at least 75% identical; at least 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99% identical; and/or all percentages of identity in between; to the amino acid sequence of SEQ ID NO: 946; and/or
(b) a light chain (LC) amino acid sequence that is at least 70% identical; at least 75% identical; at least 80% identical; at least 85% identical; at least 90% identical; at least 95% identical; at least 96% identical; at least 97% identical; at least 98% identical; at least 99% identical; and/or all percentages of identity in between; to the amino acid sequence of SEQ ID NO: 954.